Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1b dose-confirmation study of Nerofe plus doxorubicin in metastatic triple-negative breast cancer or metastatic ovarian cancer
MOH_2018-05-01_002005Phase 2Not yet recruiting
- Sponsor
- מפתח מערכת החיסון
- Start
- Mar 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibuprofen and doxorubicin in triple-negative breast cancer (TNBC) and ovarian cancer, sponsored by מפתח מערכת החיסון. Primary endpoints: Safety and tolerability of Nerofe in combination with doxorubicin and Antitumor efficacy. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
ibuprofendoxorubicin
03
Conditions
triple-negative breast cancer (TNBC)ovarian cancer
Beyond the preview
Go deeper on MOH_2018-05-01_002005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-01_002005.